FF-10501-01

DRUG2 trials

Sponsors

Fujifilm Pharmaceuticals U.S.A., Inc.

Conditions

AMLCMMLMDSMyelodysplastic Syndrome (MDS)

Phase 1

Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies

CompletedNCT02193958

Fujifilm Pharmaceuticals U.S.A., Inc.AML, CMML, MDS

Start: 2014-07-31End: 2019-10-15Updated: 2025-03-19

Phase 2

A Study of FF-10501-01 in Combination with Azacitidine in Patients with Myelodysplastic Syndrome

WithdrawnNCT03486353

Fujifilm Pharmaceuticals U.S.A., Inc.Myelodysplastic Syndrome (MDS)

Start: 2019-10-01End: 2019-10-01Updated: 2024-12-05

Related Papers

Results of a Phase 1/2a dose–escalation study of FF-10501-01, an IMPDH inhibitor, in patients with acute myeloid leukemia or myelodysplastic syndromes

Leukemia & lymphoma/Leukemia and lymphoma2020-04-077 citations